MA46466A - Formulations pharmaceutiques de protéines à viscosité réduite - Google Patents
Formulations pharmaceutiques de protéines à viscosité réduiteInfo
- Publication number
- MA46466A MA46466A MA046466A MA46466A MA46466A MA 46466 A MA46466 A MA 46466A MA 046466 A MA046466 A MA 046466A MA 46466 A MA46466 A MA 46466A MA 46466 A MA46466 A MA 46466A
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical formulations
- reduced viscosity
- proteins
- viscosity proteins
- reduced
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404861P | 2016-10-06 | 2016-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46466A true MA46466A (fr) | 2019-08-14 |
Family
ID=60294396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046466A MA46466A (fr) | 2016-10-06 | 2017-10-06 | Formulations pharmaceutiques de protéines à viscosité réduite |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11459401B2 (fr) |
| EP (1) | EP3522918A1 (fr) |
| JP (2) | JP7275027B2 (fr) |
| MA (1) | MA46466A (fr) |
| WO (1) | WO2018067987A1 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015289874A1 (en) * | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
| EA038462B1 (ru) | 2014-10-23 | 2021-08-31 | Эмджен Инк. | Снижение вязкости фармацевтических составов |
| US10434141B2 (en) | 2016-05-31 | 2019-10-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
| US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
| JP7377596B2 (ja) * | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| CN110464842B (zh) * | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | 包含抗pcsk9抗体的制剂及其用途 |
| WO2019246271A1 (fr) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur d'il-12/il-23 |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US20220257600A1 (en) | 2018-06-20 | 2022-08-18 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
| WO2019246313A1 (fr) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf |
| US20230033021A1 (en) | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| WO2020071876A1 (fr) * | 2018-10-04 | 2020-04-09 | 삼성바이오에피스 주식회사 | Trastuzumab à concentration élevée ayant une viscosité réduite ou agent de stabilisation de fragment de liaison à l'antigène associé |
| BR112021015034A2 (pt) | 2019-02-18 | 2021-10-05 | Eli Lilly And Company | Formulação de anticorpo terapêutico |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2022001896A (es) * | 2019-08-16 | 2022-06-02 | Regeneron Pharma | Formulaciones anti-c5 de alta concentracion. |
| CN111024863A (zh) * | 2019-12-31 | 2020-04-17 | 上海博威生物医药有限公司 | 一种雷莫芦单抗的肽图的测试方法 |
| MX2022015872A (es) | 2020-06-11 | 2023-05-16 | Provention Bio Inc | Metodos y composiciones para prevenir diabetes tipo 1. |
| WO2022013171A1 (fr) * | 2020-07-13 | 2022-01-20 | Merck Patent Gmbh | Excipients réducteurs de viscosité et leurs combinaisons pour formulations de protéines hautement concentrées |
| CA3198248A1 (fr) | 2020-11-10 | 2022-05-19 | Zhaoli Sun | Preparations, procedes, necessaires et formes posologiques |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| ATE531390T1 (de) | 2001-08-23 | 2011-11-15 | Genmab As | Interleukin-15-(il-15-)spezifische menschliche antikörper |
| PL1610820T5 (pl) | 2003-04-04 | 2014-01-31 | Genentech Inc | Preparaty zawierające wysokoskoncentrowane przeciwciała i białka |
| DE602005026998D1 (de) * | 2005-01-14 | 2011-04-28 | Camurus Ab | Somatostatin-analog-formulierungen |
| CA2651453C (fr) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | Analogues d'acides nucleiques bicycliques modifies en 5' |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US20130072665A1 (en) | 2007-08-23 | 2013-03-21 | Simon Mark Jackson | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
| MX2010011499A (es) | 2008-04-23 | 2010-11-12 | Amgen Inc | Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos. |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| EP2376522A4 (fr) | 2008-11-16 | 2013-12-25 | Univ Texas | Suspensions hautement concentrées de faible viscosité |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| WO2011053783A2 (fr) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Antagonistes et variants ax213 et ax132 pcsk9 |
| CA2780554C (fr) | 2009-11-17 | 2017-08-15 | Ipsen Pharma S.A.S. | Preparation pour combinaison d'hormones de croissance humaine (hgh) et de rhigf-1 |
| US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| AU2012225277A1 (en) * | 2011-03-10 | 2013-09-26 | Board Of Regents, The University Of Texas System | Protein nanoparticle dispersions |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| CA2873646C (fr) * | 2012-05-18 | 2022-04-26 | Genentech, Inc. | Formulations d'anticorps monoclonal a concentration elevee |
| WO2015196091A1 (fr) * | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Composés excipient réduisant la viscosité pour formulations à base de protéines |
| EP3193928A1 (fr) * | 2014-08-06 | 2017-07-26 | Rinat Neuroscience Corp. | Méthodes destinées à réduire le cholestérol ldl |
| WO2016046684A1 (fr) * | 2014-09-23 | 2016-03-31 | Pfizer Inc. | Traitement avec des anticorps anti-pcsk9 |
| EA038462B1 (ru) | 2014-10-23 | 2021-08-31 | Эмджен Инк. | Снижение вязкости фармацевтических составов |
-
2017
- 2017-10-06 EP EP17797203.1A patent/EP3522918A1/fr active Pending
- 2017-10-06 US US16/337,325 patent/US11459401B2/en active Active
- 2017-10-06 MA MA046466A patent/MA46466A/fr unknown
- 2017-10-06 JP JP2019518478A patent/JP7275027B2/ja active Active
- 2017-10-06 WO PCT/US2017/055620 patent/WO2018067987A1/fr active Search and Examination
-
2023
- 2023-02-27 JP JP2023028743A patent/JP2023054369A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3522918A1 (fr) | 2019-08-14 |
| JP7275027B2 (ja) | 2023-05-17 |
| JP2019530703A (ja) | 2019-10-24 |
| JP2023054369A (ja) | 2023-04-13 |
| WO2018067987A1 (fr) | 2018-04-12 |
| US11459401B2 (en) | 2022-10-04 |
| US20200024363A1 (en) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46466A (fr) | Formulations pharmaceutiques de protéines à viscosité réduite | |
| IL279464A (en) | Pharmaceutical formulation of odevixibat | |
| DK3529248T3 (da) | Farmaceutiske sammensætninger | |
| MA50541A (fr) | Formulations pharmaceutiques | |
| DK3479819T5 (da) | Stabilt væskeformigt farmaceutisk præparat | |
| MA46867A (fr) | Formulations pharmaceutiques | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| MA54716A (fr) | Réduction de la viscosité de formulations pharmaceutiques | |
| DK3357491T3 (da) | Farmaceutisk sammensætning til afgivelse af et anionisk medikament | |
| DK3532029T3 (da) | Flydende farmaceutisk sammensætning | |
| MA43705A (fr) | Formulation pharmaceutique | |
| MA45187A (fr) | Combinaisons pharmaceutiques | |
| MA44987A (fr) | Formulations de médicaments améliorées | |
| MA49837A (fr) | Compositions pharmaceutiques | |
| MA55015A (fr) | Formulations pharmaceutiques | |
| MA47516A (fr) | Composition pharmaceutique | |
| MA42964A (fr) | Préparation pharmaceutique anti-vieillissement | |
| DK3313370T3 (da) | Oftalmologisk farmaceutisk sammensætning | |
| ES2981002T3 (es) | Formulación farmacéutica | |
| DK3400017T3 (da) | Kontinuerlig kompleksering af aktive farmaceutiske ingredienser | |
| DK3280447T3 (da) | Farmaceutiske formuleringer | |
| DK3601277T3 (da) | Farmaceutisk formulering | |
| DK3310331T3 (da) | Injicerbare farmaceutiske formuleringer af lefamulin | |
| DK3302483T3 (da) | Farmaceutiske sammensætninger og anvendelse deraf |